[(2E)-6-(methylamino)cyclooct-2-en-1-yl]oxymethanethioic S-acid

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫代羰基化合物
• 英文名称: [(2E)-6-(methylamino)cyclooct-2-en-1-yl]oxymethanethioic S-acid
• 化学式: C₁₀H₁₇NO₂S
• 分子量: 215.31
• InChiKey: IRKPEKAWXOTRRZ-HWKANZROSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  39.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] BIO-ORTHOGONAL DRUG ACTIVATION<br/>[FR] ACTIVATION DE MÉDICAMENT BIO-ORTHOGONALE
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2014081301A1

  公开（公告）日：2014-05-30

  Disclosed is a kit for the administration and activation of a Prodrug. The kit comprises a Masking Moiety linked, directly or indirectly, to a Trigger moiety, which in turn is linked to a Drug, and an Activator for the Trigger moiety. The Trigger moiety comprises a dienophile and the Activator comprises a diene, whereby the dienophile is an eight-membered non- aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The Trigger and the Activator undergo a fast, bio-orthogonal reaction resulting in the release of the Masking Moiety, and activation of the drug.

  揭示了一种用于给予和激活前药的工具包。该工具包包括一个掩蔽基团，直接或间接地连接到一个触发基团，该触发基团又连接到一种药物，以及一个用于触发基团的激活剂。触发基团包括一个二烯烃，激活剂包括一个二烯，其中二烯烃是一个八元非芳香环烯基团，优选为环辛烯基团，更优选为反式环辛烯基团。触发基团和激活剂经历一个快速的生物正交反应，导致掩蔽基团的释放和药物的激活。
• [EN] AGENTS FOR CLEAVING LABELS FROM BIOMOLECULES IN VIVO<br/>[FR] AGENTS PERMETTANT DE CLIVER IN VIVO DES MARQUEURS LIÉS À DES BIOMOLÉCULES
  申请人：TAGWORKS PHARMACEUTICALS B V

  公开号：WO2020256545A1

  公开（公告）日：2020-12-24

  Disclosed herein are compounds comprising trans-cyclooctene moieties, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also be used to increase the tumor-to-blood ratio, or to more rapidly and/or conveniently achieve such an increase, of a label in targeted imaging or targeted radiotherapy in a subject, preferably a human being.

  本文所披露的化合物包括顺-环辛烯基团，组合物和套装，可用于更快地从受试者（最好是人）中清除放射性核素。所述化合物、组合物和套装还可用于增加靶向成像或靶向放射治疗中标记物的肿瘤/血液比率，或更快地和/或更方便地实现这种增加，适用于受试者（最好是人）。
• BIO-ORTHOGONAL DRUG ACTIVATION
  申请人：Tagworks Pharmaceuticals B.V.

  公开号：EP2709667B1

  公开（公告）日：2022-04-13